| 摘要: |
| 目的 探讨趋化因子受体CXCR7在卵巢上皮性癌(卵巢癌)组织中的表达情况及其临床意义。方法 采用免疫组化方法检测57例卵巢癌组织、15例良性卵巢肿瘤组织及15例正常卵巢生发上皮组织中CXCR7蛋白的阳性表达,并通过χ2检验、Kaplan-Meier法及多因素Cox回归分析等方法探讨CXCR7蛋白的阳性表达与卵巢癌患者临床病理特征及预后的相关性。结果 卵巢癌组织中CXCR7蛋白的阳性表达率为68.42%(39/57),良性卵巢肿瘤组织中CXCR7蛋白的阳性表达率为26.67%(4/15),正常卵巢生发上皮组织中CXCR7蛋白的阳性表达率为13.33%(2/15),3组间差异有统计学意义(χ2=19.97,P=0.000 1)。CXCR7蛋白的阳性表达与患者的年龄、术前CA125水平、卵巢癌肿瘤病理类型、残余肿瘤直径、腹水的含量及肿瘤的大小无关(P>0.05),而与患者FIGO分期、肿瘤的组织学分级、有无淋巴结转移及腹腔转移有关(P<0.05)。单因素及多因素分析发现,CXCR7蛋白表达水平、患者FIGO分期、肿瘤的组织学分级、有无淋巴结转移及腹腔转移与卵巢癌患者的总生存率和无瘤生存率存在统计学意义上的关联。Kaplan-Meier曲线显示,卵巢癌患者中CXCR7蛋白阳性患者的总生存率和无瘤生存率均较CXCR7蛋白阴性患者降低,差异有统计学意义(P<0.05)。结论 卵巢癌患者组织中CXCR7蛋白的表达升高,且与转移复发及预后存在密切联系,提示CXCR7可能是预测卵巢癌预后及治疗的一项重要指标。 |
| 关键词: 卵巢肿瘤 CXCR7受体 复发 肿瘤转移 预后 |
| DOI：10.16781/j.0258-879x.2016.05.0552 |
| 投稿时间：2016-02-29修订日期：2016-04-07 |
| 基金项目: |
|
| Expression and clinical significance of chemokine receptor CXCR7 in epithelial ovarian carcinoma |
| FENG Hao1,HA Fei-zha2,GU Zhong-yi1,ZHANG Jun-jie1* |
(1. Department of Obstetrics and Gynecology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China;
2. Department of Obstetrics and Gynecology, Emin County People's Hospital, Tacheng 834700, Xinjiang Uygur Autonomous Region, China
*Corresponding author) |
| Abstract: |
| Objective To investigate the expression and clinical significance of chemokine receptor CXCR7 in epithelial ovarian carcinoma (EOC) tissues. Methods Immunohistochemical technique was used to detect the protein expression of CXCR7 in 57 EOC tissues, 15 benign ovarian tumor tissues and 15 normal ovarian germinal epithelium tissues. The chi-square test, Kaplan-Meier method and multivariate Cox regression analysis were used to evaluate the relationship between the expression of CXCR7 and clinicopathological features and its prognosis. Results The positive expression rates of CXCR7 in EOC tissue, benign ovarian tumor tissue and normal ovarian germinal epithelium tissue were 68.42% (39/57), 26.67% (4/15) and 13.33% (2/15), respectively (χ2=19.97, P=0.000 1). The positive expression of CXCR7 was significantly correlated with the International Federation of Gynecology and Obstetrics (FIGO) stages, histological grade, lymph node metastasis and peritoneal metastasis (P<0.05), but not with age, preoperative CA125 level, histological type of EOC, residual tumor diameter, ascites content, or tumor size (P>0.05). Univariate analysis and multivariate analysis results showed that the positive expression of CXCR7, FIGO stage, histological grade, lymph node metastasis and peritoneal metastasis were statistically correlated with the overall survival and disease-free survival of EOC patients. Kaplan-Meier curve revealed that both overall survival and disease-free survival in EOC patients with positive expression of CXCR7 were significantly lower than those in EOC patients with negative CXCR7 (P<0.05). Conclusion The high expression of CXCR7 is closely related to the recurrence and metastasis in EOC patients, which indicates that CXCR7 might be a potential predictor and an important therapeutic indicator of EOC. |
| Key words: ovarian neoplasms CXCR7 receptors recurrence neoplasm metastasis prognosis |
